The U.S. Food and Drug Administration has approved Foster City, Calif.-based Gilead's Sovaldi (sofosbuvir) to treat chronic Hepatitis C.
Sovaldi treats certain types of Hepatitis C viruses without needing to co-administer interferon, according to the news release.
Sovaldi blocks a protein the Hepatitis C virus uses to duplicate itself. The drug should be used as part of a combination antiviral treatment.
This is the second drug in two weeks the FDA has cleared to treat Hepatitis C. The FDA approved Olysio on Nov. 22.
More Articles on the FDA:
4 Latest FDA Approvals
FDA Issues Safety Communication on Certain HeartStart AEDs from Philips Medical Systems
FDA Recalls Spacelabs Healthcare's Anesthesia Workstations